A post hoc analysis of the HOST-EXAM trial showed that clopidogrel monotherapy was more effective than aspirin monotherapy in patients who underwent PCI and remained event-free for 6-18 months on DAPT, regardless of bleeding risk or PCI complexity. Thrombotic events and bleeding were more common in high bleeding risk patients, but the benefits of clopidogrel monotherapy were consistent across all patients. The study, led by Jeehoon Kang, MD, Seoul National University, was published in JAMA Cardiology. Limitations include the study being hypothesis generating and conducted in East Asian patients. Overall, clopidogrel monotherapy showed long-term benefits in all patients following PCI.
Source link
Clopidogrel Tops Aspirin Post-PCI, Even in High-Risk Cases
